XENE - Why Is Neurocrine Biosciences Stock Trading Lower Today? | Benzinga
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia.
The investigational selective NaV 1.6 inhibitor, NBI-921352, licensed from Xenon Pharmaceuticals Inc (NASDAQ: XENE), failed to demonstrate meaningful seizure frequency reduction in the Phase 2 dose-finding study as adjunctive therapy in adults with focal onset seizures.
No further development with NBI-921352 in Focal Onset Seizure (FOS) is currently planned.
Neurocrine is reviewing the data from the FOS study to understand any potential implication for its ongoing study in SCN8A-developmental epileptic encephalopathy and will provide an update once this review is complete.
The ...